Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News Feature
  • Published:

India's top drug regulator

Nature Medicine volume 20, pages 802–805 (2014)Cite this article

Subjects

Two years ago, Gyanendra Nath Singh was tasked with overseeing India's drug regulatory agency. Despite the US having temporarily suspended a suite of trials in India and banned drug imports from several manufacturers there over the last couple of years, Singh says progress is being made. Killugudi Jayaraman reports.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Author information

Authors and Affiliations

  1. Killugudi Jayaraman is a science writer based in Bangalore.,

    Killugudi Jayaraman

Authors
  1. Killugudi Jayaraman
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Jayaraman, K. India's top drug regulator. Nat Med 20, 802–805 (2014). https://doi.org/10.1038/nm0814-802

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm0814-802

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research